Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-128800 in moderate to severe chronic plaque psoriasis
2008-001443-19Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2008
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing ACT-128800 with Placebo (2 arms). Primary endpoint: PASI percent change from baseline at Week 6. Started Jul 2008; status: completed.
02
Drugs
ponesimod
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2008-001443-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001443-19.